Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure
Key facts
- Where
- Bergamo és Milan, OlaszországSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Forrás: NCT07560982: ki vehet részt
Where in Olaszország
- ASST Ospedale Papa Giovanni XXIIIBergamo, OlaszországToborzás még nem indult
- IRCCS Ospedale San RaffaeleMilan, OlaszországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Università Vita-Salute San Raffaele
- Trial code
- NCT07560982
- Record updated
- 2026. július 6.
- Original description
A Prospective Observational, Multi-Center, Real-World Pharmacological Study Evaluating Adherence to Guideline-Directed Medical Therapy Using the Four-Pillar Strategy in Patients with Advanced Heart FailureRead full original descriptionShow less
Evaluating Adherence to Guideline- Directed Medical Therapy Using the Four-Pillar Strategy in Patients With Advanced Heart Failure: the Advanced Heart Failure Unified Board (Ad-HUB) Study
A Prospective Observational, Multi-Center, Real-World Pharmacological Study Evaluating Adherence to Guideline-Directed Medical Therapy Using the Four-Pillar Strategy in Patients with Advanced Heart Failure
Inclusion: Age > 18 and < 75 years; Heart failure with left ventricular ejection fraction ≤ 35%; Persistent symptoms of heart failure, New York Heart Association class III or IV; Requirement for high-dose diuretic therapy, specifically Furosemide > 50 mg/day orally as per routine clinical practice; At least one of the following additional indicators of severity or refractoriness:; need for progressive escalation of diuretics,; intolerance to optimized medical therapy,; persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and/or MitraClip; Ability and willingness to provide written informed consent for participation and for the processing of clinical data for research purposes.
Exclusion: Good response to optimized conventional guideline-directed medical therapy; Mild or absent symptoms (New York Heart Association class I-II); Extreme frailty or severe non-reversible disability, or psychiatric or cognitive disorders preventing adherence to follow-up; Left ventricular ejection fraction > 35%; Age ≤ 18 years or ≥ 75 years; Pregnant or breastfeeding women.